ALDR Overview
Upcoming Projects (ALDR)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (ALDR)
-
Don’t see a project related to the company you care about? Create your own!
Expired Projects (ALDR)
-
A Second Opinion: Preparing for Eptinezumab's data in Chronic Migraine after study changes and additional data from Erenumab
Tickers: ALDR, AMGN, TEVA, NVS
Execute By: May 17, 2017
Upcoming & Overdue Catalysts (ALDR)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (ALDR)
-
Top line data from PROMISE 2, a Phase 3 study of Eptinezumab in 1,500 Chronic Migraine patients
Tickers: ALDR, TEVA, AMGN
Occurred on: Feb 26, 2018 -
PROMISE 2 Phase 3 trial in Chronic Migraine Top Line data expected first half of 2018
Ticker: ALDR
Occurred on: Jan 08, 2018 -
Alder (ALDR) Expects Top-Line Data from Phase III PROMISE 1 Trial Evaluating ALD403 in Frequent Episodic Migraines in H1 2017
Ticker: ALDR
Occurred on: Jun 27, 2017 -
Alder (ALDR) to Initiate Phase III PROMISE 2 Study Evaluating ALD403 in Frequent Episodic Migraines in H2 2016
Ticker: ALDR
Occurred on: Nov 28, 2016 -
Alder (ALDR) Plans to Announce Top-Line Data From 24 Week Phase 2b Study of ALD-403 in Chronic Migraine Patients By Mid-Year 2016
Ticker: ALDR
Occurred on: Sep 15, 2016 -
Alder (ALDR) Announces Phase 2b Data for ALD403 in Prevention of Chronic Migraines
Ticker: ALDR
Occurred on: Mar 28, 2016 -
Phase 2b data of ALD403 fo migraine due 1Q 2016
Ticker: ALDR
Occurred on: Mar 28, 2016 -
Alder (ALDR) Initiates Phase III PROMISE 1 Trial Evaluating ALD403 for the Prevention of Frequent Episodic Migraines
Ticker: ALDR
Occurred on: Oct 13, 2015 -
Alder (ALDR) Presents Positive Data from Phase 2 Proof-of-Concept Study of ALD403 for the Prevention of Episodic Migraine
Ticker: ALDR
Occurred on: May 15, 2015
Strategic Initiatives (ALDR)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
